TP53 and head and neck squamous cell carcinoma: Second, combined modified vaccinia virus Ankara vaccine expressing p53 (p53MVA vaccine), and immune checkpoint PD-1 and PD-L1 inhibitor pembrolizumab are being investigated in combination in HNSCC and other incurable solid tumors that have failed prior therapy [183].